Door To Unloading With IMPELLA CP System in Acute Myocardial Infarction - Safety and Feasibility Study

NCT ID: NCT03000270

Last Updated: 2019-05-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-04-11

Study Completion Date

2018-08-16

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Direct active unloading of the left ventricle with the Impella CP System prior to PPCI in patients with ST-elevation myocardial infarction (STEMI) is safe and feasible

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A multi-center, prospective, randomized, two-arm feasibility trial to assess the potential role of unloading with the Impella CP prior to revascularization in reducing infarct size. The study design includes 1:1 randomization between: 1) Delay Arm: 30 minutes of unloading with Impella CP prior to primary percutaneous coronary intervention (PPCI); and 2) Immediate Arm: initiation of Impella CP unloading followed immediately by PPCI.

Study Hypothesis: Direct active unloading of the left ventricle with the Impella CP System prior to PPCI in patients with ST-elevation myocardial infarction (STEMI) is safe and feasible

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

STEMI

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Prolonged unloading prior to PPCI

Activation of Impella CP for a 30 minute duration prior to primary percutaneous coronary intervention

Group Type ACTIVE_COMPARATOR

Impella unloading prior to PPCI

Intervention Type DEVICE

Impella unloading prior to PPCI

Immediate unloading prior to PPCI

Activation of Impella CP immediately prior to primary percutaneous coronary intervention

Group Type ACTIVE_COMPARATOR

Impella unloading prior to PPCI

Intervention Type DEVICE

Impella unloading prior to PPCI

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Impella unloading prior to PPCI

Impella unloading prior to PPCI

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 21-80 years
* First myocardial infarction
* Acute anterior STEMI with ≥ 2 mm in 2 or more contiguous anterior leads or≥ 4 mm total ST-segment deviation sum in the anterior leads
* Signed Informed Consent

Exclusion Criteria

* Cardiogenic shock defined as: systemic hypotension (systolic BP less than 90 mmHg or the need for inotropes/pressors to maintain a systolic BP Greater than 90mmHg) plus one of the following: any requirement for pressors/inotropes prior to arrival at the cath lab, clinical evidence of end organ hypoperfusion, lactate level greater than 2.5mmol/L
* Inferior STEMI or suspected right ventricular failure
* Suspected or known pregnancy
* Suspected active infection
* History or known hepatic insufficiency prior to catheterization
* On dialysis therapy
* Known contraindication to:
* Undergoing MRI or use of gadolinium
* Heparin, pork, pork products or contrast media
* Receiving a drug-eluting stent
* Participation in the active treatment or follow-up phase of another clinical study of an investigational drug or device
Minimum Eligible Age

21 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Abiomed Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Banner Good Samaritan Medical Center

Phoenix, Arizona, United States

Site Status

Wellstar/Kennestone Hospital

Marietta, Georgia, United States

Site Status

Detroit Medical Center

Detroit, Illinois, United States

Site Status

Advocate Edward Hospital

Oakbrook Terrace, Illinois, United States

Site Status

Tufts Medical Center

Boston, Massachusetts, United States

Site Status

ABIOMED, Inc.

Danvers, Massachusetts, United States

Site Status

Baystate Medical Center

Springfield, Massachusetts, United States

Site Status

Henry Ford Hospital

Detroit, Michigan, United States

Site Status

Spectrum

Grand Rapids, Michigan, United States

Site Status

Hackensack Medical Center

Hackensack, New Jersey, United States

Site Status

University of Buffalo Hospital

Buffalo, New York, United States

Site Status

Northwell Health

Manhasset, New York, United States

Site Status

Albert Einstein Medical Center

Philadelphia, Pennsylvania, United States

Site Status

Greenville Health System

Greenville, South Carolina, United States

Site Status

West Virginia University Hospital

Morgantown, West Virginia, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Kapur NK, Alkhouli MA, DeMartini TJ, Faraz H, George ZH, Goodwin MJ, Hernandez-Montfort JA, Iyer VS, Josephy N, Kalra S, Kaki A, Karas RH, Kimmelstiel CD, Koenig GC, Lau E, Lotun K, Madder RD, Mannino SF, Meraj PM, Moreland JA, Moses JW, Kim RL, Schreiber TL, Udelson JE, Witzke C, Wohns DHW, O'Neill WW. Unloading the Left Ventricle Before Reperfusion in Patients With Anterior ST-Segment-Elevation Myocardial Infarction. Circulation. 2019 Jan 15;139(3):337-346. doi: 10.1161/CIRCULATIONAHA.118.038269.

Reference Type RESULT
PMID: 30586728 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

http://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.118.038269

Unloading the Left Ventricle Before Reperfusion in Patients With Anterior ST-Segment-Elevation Myocardial Infarction.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

DTU - Safety and Feasibility

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Delayed Postconditioning
NCT01483755 COMPLETED PHASE2
CARESS in Acute Myocardial Infarction
NCT00220571 COMPLETED PHASE3
Remote Ischemic Preconditioning in Primary PCI
NCT00435266 COMPLETED PHASE2/PHASE3